Serine phosphorylation of glutathione S-transferase P1 (GSTP1) by PKCα enhances GSTP1-dependent cisplatin metabolism and resistance in human glioma cells

Biochemical Pharmacology

Volumn 80, Issue 9, 2010, Pages 1343-1355

  Singh, Simendra ^a   Okamura, Tatsunori ^a   Ali Osman, Francis ^a  

^a DUKE CANCER INSTITUTE   (United States)

Author keywords

Cisplatin; GSTP1; Phosphorylation; PKC

Indexed keywords

BISINDOLYLMALEIMIDE; BISINDOLYLMALEIMIDE 1; CASPASE 3; CASPASE 7; CISPLATIN; CYTOCHROME C; ETACRYNIC ACID; GLUTATHIONE; GLUTATHIONE TRANSFERASE P1; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN BAX; PROTEIN KINASE C ALPHA; SERINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; BISINDOLYLMALEIMIDE I; GSTP1 PROTEIN, HUMAN; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; PRKCA PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS LINKING; CYTOSOL; DNA CROSS LINKING; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PROCESSING; ANTAGONISTS AND INHIBITORS; GENETICS; GLIOMA; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN TRANSPORT; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GLIOMA; GLUTATHIONE S-TRANSFERASE PI; HUMANS; INDOLES; MALEIMIDES; PHOSPHORYLATION; PROTEIN KINASE C-ALPHA; PROTEIN TRANSPORT; RNA, SMALL INTERFERING; SERINE; TETRADECANOYLPHORBOL ACETATE;

EID: 77956652449     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.07.019     Document Type: Article

References (54)

1. Mora J., Cruz O., Gala S., Navarro R. Successful treatment of childhood intramedullary astrocytomas with irinotecan and cisplatin. Neuro-Oncology 2007, 9:39-46.
2. Mustacchi G., Muggia M., Milani S., Ceccherini R., Leita M.L., Dellach C. A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer. Ann Oncology 2002, 13:1730-1736.
3. Gedlicka C., Formanek M., Selzer E., Burian M., Kornfehl J., Fiebiger W., Cartellieri M., et al. Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oncology 2002, 63:145-150.
4. Ozols R.F., Bookman M.A., du Bois A., Pfisterer J., Reuss A., Young R.C. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncology 2006, 103:1-6.
5. Langer C.J., Manola J., Bernardo P., Kugler J.W., Bonomi P., Cella D., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002, 94:173-181.
6. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
7. Ali-Osman F., Brunner J.M., Kutluk T.M., Hess K. Prognostic significance of Glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res 1997, 3:2253-2261.
8. Su F.H., Hu X., Jia W., Gong C., Song E., Hamar P. Glutathione S-transferase π indicates chemotherapy resistance in breast cancer. J Surg Res 2003, 113:102-108.
9. Howells R.E., Dhar K.K., Hoban P.R., Jones P.W., Fryer A.A., Redman C.W., et al. Association between glutathione-S-transferase GSTP1 genotypes, GSTP1 over-expression, and outcome in epithelial ovarian cancer. Int J Gynecol Cancer 2004, 14:242-250.
10. Krajinovic M., Labuda D., Sinnett D. Glutathione S-transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemia. Pharmacogenetics 2002, 12:655-658.
11. Wang X., Pavelic Z.P., Li Y., Gleich L., Gartside P.S., Pavelic L., et al. Overexpression and amplification of Glutathione S-transferase pi gene in head and neck squamous cell carcinomas. Clin Cancer Res 1997, 3:111-114.
12. Zhang Y., Qu X., Jing W., Hu X., Yang X., Hou K., et al. GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: regulation by promoter methylation and extracellular regulated kinase signaling. Anti-Cancer Drugs 2009, 20:208-214.
13. Tew K.D., Monks A., Barone L., Rosser D., Akerman G., Montali J.A., et al. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. Mol Pharm 1996, 50:149-159.
14. Coles B.F., Kadlubar F.F. Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs. Biofactors 2003, 17:115-130.
15. Adler V., Yin Z., Fuchs S.Y., Benezra M., Rosario L., Pincus M.R., et al. Regulation of JNK signaling by GSTp. EMBO J 1999, 18:1321-1334.
16. Lo H.W., Ali-Osman F. Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr Opin Pharmacol 2007, 4:376-474.
17. Cumming R.C., Lightfoot J., Beard K., Youssoufian H., O'Brien P.J., Buchwald M. Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1. Nat Med 2001, 7:814-820.
18. Wu Y., Fan Y., Xue B., Luo L., Shen J., Zhang S., et al. Human glutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2-ASK1 signals. Oncogene 2006, 25:5787-5800.
19. Piredda L., Farrace M.G., Lo Bello M., Malorni W., Melino G., Petruzzelli R., et al. Identification of 'tissue' transglutaminase binding proteins in neural cells committed to apoptosis. FASEB J 1999, 13:355-364.
20. Ishikawa T., Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. J Biol Chem 1993, 268:20116-20125.
21. Lo H.-W., Antoun G.R., Ali-Osman F. The human Glutathione S-transferase P1 protein is phosphorylated and its metabolic function enhanced by the Ser/Thr protein kinases, cAMP-dependent protein kinase and protein kinase C, in glioblastoma cells. Cancer Res 2004, 64:9131-9138.
22. Martiny-Baron G., Fabbro D. Classical PKC isoforms in cancer. Pharmacol Res 2007, 55:477-486.
23. Mandil R., Ashkenazi E., Blass M., Kronfeld I., Kazimirsky G., Rosenthal G., et al. Protein kinase Cα and protein kinase Cδ play opposite roles in the proliferation and apoptosis of glioma cells. Cancer Res 2001, 61:4612-4619.
24. Cho K.-K., Mikkelsen T., Lee Y.J., Jiang F., Chopp M., Rosenblum M.L. The role of protein kinase Cα in U-87 glioma invasion. Int J Dev Neurosci 1999, 17:447-461.
25. Pollack I.F., Kawecki S., Lazo J.S. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. J Neurosurg 1996, 84:1024-1032.
26. Geiger T., Müler M., Dean N.M., Fabbro D. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Design 1998, 13:35-45.
27. Ruvolo P.P., Deng X., Carr B.K., May W.S. A functional role for mitochondrial protein kinase Cα in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 1998, 273:25436-25442.
28. Leiradl M., Sioud M. Ribozyme inhibition of the protein kinase Cα triggers apoptosis in glioma cells. Br J Cancer 1999, 80:1558-1564.
29. Kim J.S., Lee J.M., Chwae Y.J., Kim Y.H., Lee J.H., Kim K., et al. Cisplatin-induced apoptosis in Hep3B cells: mitochondria-dependent and -independent pathways. Biochem Pharmacol 2004, 67:1459-1468.
30. Murphy K.M., Ranganathan V., Farnsworth M.L., Kavallaris M., Lock R.B. Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. Cell Death Diff 2000, 7:102-111.
31. Ali-Osman F. Culture of human normal brain and brain tumors for cellular, molecular and pharmacological studies. Methods in Molecular Medicine, Human Cell Culture Protocols 1996, 63-80. Humana Press. G.E. Jones (Ed.).
32. Senft A.P., Dalton T.P., Shertzer H.G. Determining glutathione and glutathione disulfide using the fluorescence probe o-phthalaldehyde. Anal Biochem 2000, 280:80-86.
33. Bradford M.M. A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
34. Habig W.H., Pabst M.J., Jakoby W.B. Glutathione S-transferases. The first enzyme step in mercapturic acid formation. J Biol Chem 1974, 249:7130-7139.
35. Habig W.H., Jakoby W.B. Assays for differentiation of glutathione S-transferases. Meth Enzy 1981, 77:398-405.
36. Anilanmert B., Yalçin G., Ariöz F., Dölen E. The spectrophotometric determination of cisplatin in urine, using o-phenylenediamine as derivatizing agent. Anal Lett 2001, 34:113-123.
37. Tse W.C., Boger D.L. A fluorescent intercalator displacement assay for establishing DNA binding selectivity and affinity. Acc Chem Res 2004, 37:61-69.
38. Ali-Osman F., Rairkar A., Young P. Formation and repair of 1,3-bis-(2-chloroethyl)-1-nitrosourea and cisplatin induced total genomic DNA interstrand crosslinks in human glioma cells. Cancer Biochem Biophys 1995, 14:231-241.
39. Bredel M., Pollack I.F. The role of protein kinase C (PKC) in the evolution and proliferation of malignant gliomas, and the application of PKC inhibition as a novel approach to anti-glioma therapy. Acta Neurochir 1997, 139:1000-1013.
40. da Rocha A.B., Mans D.R., Lenz G., Fernandes A.K., de Lima C., Monteiro V.F., et al. Protein kinase C-mediated in vitro invasion of human glioma cells through extracellular-signal-regulated kinase and ornithine decarboxylase. Pathobiology 2000, 68:113-123.
41. Koivunen J., Aaltonen V., Koskela S., Lehenkari P., Laato M., Peltonon J. Protein kinase Cα/β inhibitor Gö6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells. Cancer Res 2004, 64:5693-5701.
42. Gill P.K., Gescher A., Gant T.W. Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes α and θ. Eur J Biochem 2001, 268:4151-4157.
43. Basu A., Weixel K.M. Comparison on protein kinase C activity and isoform expression in cisplatin-sensitive and -resistant ovarian carcinoma cells. Int J Cancer 1995, 62:457-460.
44. Orlandi L., Binda M., Folini M., Bearzatto A., Villa R., Daidone M.G., et al. Ribozyme-mediated inhibition of PKCalpha sensitizes androgen-independent human prostrate cancer cells to cisplatin-induced apoptosis. Prostrate 2003, 54:133-143.
45. Su F., Hu X., Jia W., Gong C., Song E., Hamar P. Glutathione S-transferase pi indicates chemotherapy resistance in breast cancer. J Surg Res 2003, 113:102-108.
46. Huang G., Mills L., Worth L.L. Expression of human glutathione S-transferase P1 mediates the chemosensitivity of osteosarcoma cells. Mol Cancer Ther 2007, 6:1610-1619.
47. Fruehauf J.P., Brem H., Brem S., Sloan A., Barger G., Huang W., et al. In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res 2006, 12:4523-4532.
48. Cullen K.J., Newkirk K.A., Schumaker L.M., Aldosari N., Rone J.D., Haddad B.R. Glutathione S-transferase π associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res 2003, 63:8097-8102.
49. Ali-Osman F., Stein D.E., Renwick A. Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines. Cancer Res 1990, 50:6976-6980.
50. Righetti S.C., Perego P., Carenini N., et al. Molecular alterations of cells resistant to platinum drugs: Role of PKCα. Biochim Biophys Acta 2006, 1763:93-100.
51. Mohanty S., Huang J., Basu A. Enhancement of cisplatin sensitivity of cisplatin-resistant human cervical carcinoma cells by Bryostatin 1. Clin Cancer Res 2005, 11:6730-6737.
52. Kluck R.M., Bossy-Wetzel E., Green D.R., Newmeyer D.D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997, 275:1132-1136.
53. Cheng E.H., Wei M.C., Weiler S., Flavell R.A., Mak T.W., Lindsten T., et al. Bcl-2 and Bcl-X sequester BH3 domain-only molecules preventing Bax- and bak-mediated mitochondrial apoptosis. Mol Cell 2001, 8:705-711.
54. Sordet O., Rébé C., Leroy I., Bruey J.M., Garrido C., Miguet C., et al. Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. Blood 2001, 97:3931-3940.